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The soluble guanylate cyclase 
stimulator riociguat reduces 
fibrogenesis and portal pressure in 
cirrhotic rats
Philipp Schwabl  1,2, Ksenia Brusilovskaya1,2, Paul Supper1,2, David Bauer1,2, Philipp 
Königshofer  1,2, Florian Riedl1,2, Hubert Hayden1,2, Claudia Daniela Fuchs1, Judith Stift3, 
Georg Oberhuber3, Stefan Aschauer4, Diana Bonderman4, Thorsten Gnad5, Alexander 
Pfeifer5, Frank Erhard Uschner6, Jonel Trebicka6,7,8,9, Nataliya Rohr-Udilova1,2, Bruno Karl 
Podesser10, Markus Peck-Radosavljevic1,2, Michael Trauner1 & Thomas Reiberger  1,2
In cirrhotic patients, portal hypertension (PHT) deteriorates survival, yet treatment options are 
limited. A major contributor to increased intrahepatic vasoconstriction in PHT is dysfunctional nitric-
oxide signaling. Soluble guanylate cyclase (sGC) is the receptor of nitric-oxide and can be stimulated 
by riociguat. Riociguat is approved for pulmonary hypertension but has not been studied in liver 
cirrhosis. In this study we assessed the effects of riociguat on PHT and liver fibrosis in cholestatic (bile 
duct ligation, BDL) and toxic (carbon-tetrachloride, CCl4) rat models. In cirrhotic livers sGC expression 
was upregulated. In BDL rats, riociguat reduced liver fibrosis and decreased portal pressure without 
affecting systemic hemodynamics. In an early BDL disease stage, riociguat decreased bile duct 
proliferation, improved sinusoidal vascular dysfunction and inhibited angiogenesis. In advanced BDL 
riociguat exhibited anti-inflammatory effects. In CCl4 rats the beneficial effects of riociguat treatment 
were less pronounced and confined to an early disease stage. Similarly, in patients with cholestatic 
cirrhosis and PHT nitrates (that induce sGC activity) decreased portal pressure more effectively than 
in patients with non-cholestatic etiology. We also found an improvement of transaminases in patients 
with pulmonary hypertension receiving riociguat. Our findings support the clinical development of sGC 
stimulators in patients with cirrhotic PHT.
In liver cirrhosis intrahepatic vascular resistance is increased – causing portal hypertension (PHT)1. In turn, PHT 
may subsequently trigger development of hyperdynamic circulation2 and severe complications, such as variceal 
bleeding3 or ascites4. Non-selective betablockers (which reduce hepatic inflow)5 and nitrates (nowadays rarely 
used due to systemic side effects)6 are the only available medical treatments for PHT – but not all patients show a 
sufficient decrease of portal pressure1. Hence novel therapeutic targets7, such as the nuclear receptors PPARγ8 or 
FXR9, and the soluble guanylate cyclase (sGC) are currently explored.
Intrahepatic vascular resistance in cirrhosis is determined by both structural (i.e. fibrosis, vascular remode-
ling) and functional abnormalities (i.e. sinusoidal vasoconstriction, endothelial dysfunction)10. Endothelial dys-
function and sinusoidal vasoconstriction are driven by inflammation, oxidative stress and by an imbalance of 
vasodilators and vasoconstrictors. Nitric oxide (NO) represents the most important biogenic vasodilator, while in 
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cirrhotic livers, both the production of and the response to NO are severely dysregulated11. The NO downstream 
signaling target sGC mediates vasodilation by catalyzing the reaction from GTP to cGMP12. The enzyme activity 
is predominantly regulated by a heme/Fe(II) group, which senses NO12,13. However, under conditions of oxidative 
stress, Fe(II) may be oxidized to Fe(III), thereby decreasing responsiveness to NO and thus deteriorating enzyme 
kinetics14. Pharmacologically, sGC activity can be increased using sGC stimulators such as riociguat (RIO)15. RIO 
targets sGC via an allosteric binding site and potentiates its sensitivity to low levels of bioavailable NO16. Direct 
modulation of sGC activity - downstream from NO - might be more beneficial than affecting NO production 
itself, since most detrimental effects of NO are cGMP-independent, while cytoprotective actions of NO are medi-
ated via sGC17. Moreover, sGC stimulation by RIO may be more resistant against the negative cGMP-dependent 
protein kinase feedback loop18 or S-nitrosylation in stress conditions19, both limiting sGC activity.
In preclinical studies RIO has been shown to exert antihypertensive, antifibrotic and antiinflammatory 
effects, and to reduce vascular remodeling20. Recently, RIO has been approved for the treatment of pulmonary 
hypertension21,22. Two experimental studies investigated the effects of the sGC activator BAY 60–2770 in exper-
imental cirrhosis: Knorr et al. demonstrated first, that BAY 60–2770 exhibits antifibrotic effects in rat models of 
CCl4-fibrosis and pig-serum induced liver injury23. Xie et al. confirmed these findings in a thioacetamide rat 
model and also observed an amelioration of sinusoidal architecture after BAY 60–2770 treatment24. Currently 
there are no data on the effects of sGC stimulation on PHT. However, prevention of cGMP degradation by 
phosphodiesterase-5-inhibitors (PDE5i), significantly reduced portal pressure (PP) in two clinical studies25,26. In 
line, PDE5i also reduced liver fibrosis, improved endothelial dysfunction and decreased PHT in cirrhotic rats27,28.
Here, we investigate the effects of RIO on PHT and liver fibrosis in rats with early and advanced biliary (BDL) 
and hepatotoxic (CCl4) cirrhosis (Fig. 1). Furthermore, we aim to dissect the molecular mechanisms involved in 
RIO-induced modulation of sinusoidal vasotonus, angiogenesis, and inflammation.
Results
Riociguat ameliorates portal hypertension. The beneficial effects of sGC simulation are more 
pronounced in cholestatic cirrhosis than in toxic cirrhosis. All cirrhotic rats presented with signifi-
cantly elevated PP compared to healthy controls and the degree of PHT increased with longer BDL duration (early 
BDL: 13.2 ± 2.5 mmHg, advanced BDL: 15.5 ± 1.6) and higher toxin exposure (early CCl4: 8.2 ± 0.9; advanced 
CCl4: 11.6 ± 2.5) (Table 1). In BDL rats, RIO significantly decreased PP in the early BDL (−24.1%; p = 0.048) as 
well as in the advanced BDL (−23.9%; p = 0.003) setting compared to vehicle (VEH) treated animals. Notably, 
RIO did not affect portosystemic shunting nor systemic hemodynamics. In the early toxic fibrosis model, RIO sig-
nificantly decreased PP (−15.8%; p = 0.016), superior mesenteric artery blood flow (SMABF; −18.9%; p = 0.014) 
and tended to lower portosystemic shunting without deteriorating systemic hemodynamics. In contrast, in 
advanced CCl4 cirrhotic animals RIO did not exert beneficial effects on hepatic or systemic hemodynamics. Rats 
Figure 1. Study design and treatment groups. Riociguat or vehicle were gavaged once daily for 2–3 weeks to 
rats in early and advanced stages of cholestatic (BDL) or toxic (CCl4) cirrhosis, and to respective controls. 
Subsequently, portal and systemic hemodynamics were assessed and the degree of liver fibrosis quantified. The 
PPVL model was used to study hemodynamic effects in non-cirrhotic prehepatic portal hypertension.
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of the advanced CCl4 cirrhosis group presented an extensive disease with weight loss and death of five animals 
(n = 2 CCl4-VEH; n = 3 CCl4-RIO).
Riociguat exerts antifibrotic activity in cholestatic and toxic models. Both liver disease models 
presented with significantly increased hepatic fibrosis, as compared to healthy controls. A significant decrease in 
chromotrope-aniline-blue (CAB) stained area and hepatic hydroxyproline (HP) content was evident after RIO 
treatment in BDL rats with early (CAB: −44%; HP: −50%) and also advanced (CAB: −36%; HP: −29%) choles-
tatic cirrhosis (Fig. 2A–D). In the early cholestatic disease model, this effect was accompanied by less cytokeratin 
19 (CK19) positive area in liver histology (−42%), indicating a reduction of ductular proliferation (Fig. 2E). In 
CCl4 rats, the antifibrotic effects were less pronounced. Only in the early CCl4 setting, a significant decrease of 
CAB stained area was detected.
Riociguat favours intrahepatic vasodilation. In early cholestatic (BDL) cirrhosis, western blot analysis 
of vasoactive proteins expression revealed a strong reduction of moesin phosphorylation (p-moesin) and myosin 
light chain production upon treatment with RIO (Fig. 3A). This was accompanied by a decrease of intrahepatic 
vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor beta (PDGFβ) expres-
sion, while levels of endothelial nitric oxide synthase (eNOS) did not change (Fig. 3B). In BDL-RIO rats with 
advanced cirrhosis, there was still a trend towards less moesin phosphorylation and myosin expression notable 
(Fig. 3C). However the increased expression of VEGFR2 and PDGFβ after bile duct ligation remained unchanged 
upon RIO treatment. In contrast, in advanced BDL rats RIO caused an increase in total (t-eNOS) and phospho-
rylated eNOS (p-eNOS) (Fig. 3D). Yet, intrahepatic NOx levels were not significantly affected by RIO - neither in 
early nor in advanced stage of cholestatic/BDL cirrhosis (Supplementary Fig. S1).
Notably, also in rats with early CCl4 cirrhosis RIO significantly decreased hepatic moesin phosphorylation 
(p-moesin) and myosin light chain production. Yet in this group RIO had no significant effect on eNOS, VEGFR2 
or PDGFβ expression (Supplementary Fig. S2A,B).
Riociguat reduces hepatic inflammation. BDL causes hepatic inflammation and induced expression of 
the proinflammatory cytokines vascular cell adhesion protein 1 (VCAM), tumor necrosis factor alpha (TNFα), 
interleukin 1 beta (IL1β) and monocyte chemoattractant protein 1 (MCP1). In the early BDL model the expres-
sion differences of these biomarkers were mostly non-significant, when compared to SO-VEH. Thus also the 
impact of RIO treatment attained no statistical significance, even though mean VCAM and TNFα expression 
were decreased by 48.5% and 46.7%, respectively (Fig. 4A).
However, in advanced cholestasis, RIO treatment resulted in a significant decrease of TNFα mRNA and 
tended to reduce MCP1 expression, while VCAM and IL1β remained unchanged (Fig. 4B). To confirm this sig-
nal, hepatic TNFα protein content was measured and indeed RIO normalized the upregulation of hepatic TNFα 
in BDL rats (Fig. 4C). Ultimately, BDL-RIO rats also showed reduced serum levels of aspartate transaminase 
(AST; −39%) and alanine transaminase (ALT; −27%) as compared to BDL-VEH animals (Fig. 4D). To assess 
the impact on hepatic macrophage infiltration, cluster of differentiation 68 (CD68+) was stained in liver slides. 
In line with the previous observations, RIO treatment significantly decreased CD68+ area in rats with advanced 
cholestasis (Fig. 4E).
Riociguat inhibits the fibrogenic phenotype of hepatic stellate cells in vivo and in vitro. To 
further investigate the molecular effects of RIO, LX-2 HSCs were treated with RIO, where a significant decrease 
of alpha smooth muscle actin (αSMA) gene expression was observed (Fig. 5A). Since αSMA is mainly expressed 
in HSCs, hepatic αSMA content was quantified by Western Blot and αSMA-positive area was quantified in vivo 
by histological analysis. In BDL rats with early cirrhosis, RIO treatment decreased intrahepatic αSMA protein 
expression and αSMA positive stained area in liver slides (5.66 ± 2.43 vs. 3.12 ± 1.92%; p = 0.013) (Fig. 5B,C). 
We also observed a non-significant decrease in hepatic αSMA protein content and a trend towards lower 
αSMA expression in liver histology of BDL-RIO rats with advanced cirrhosis (Fig. 5B,C). Yet, in CCl4 rats only 
minor changes of hepatic αSMA were detected, as quantified in liver histology (Fig. 5D) and by protein content 
(Supplementary Fig. S2C,D).
sGC is expressed in the liver and upregulated in BDL rats. In healthy rat livers, we detected expres-
sion of sGC subunits α1 and β1 mostly in hepatocytes and hepatic stellate cells (HSC), but also in liver sinusoidal 
endothelial cells (LSEC) and to a very low extent in Kupffer cells (Fig. 6A–D). In BDL cirrhotic animals, we 
measured a significant upregulation of the sGC β1 subunit in HSCs (Fig. 6D) and additionally a trend towards 
increased sGC expression in other liver cell subsets. In contrast, α1 expression remained unchanged. We thus 
further investigated the impact of BDL on expression of the less common α2 and β2 subunits in HSCs. Here we 
noted a significant downregulation of the β2 subunit, while again expression of the α2 subunit was unaffected by 
cholestasis (Fig. 6E).
Riociguat decreases portal pressure in prehepatic portal hypertension, but at the cost of 
increased portosystemic shunting. In a non-cirrhotic portal hypertensive partial portal vein liga-
tion (PPVL) model, RIO also significantly decreased PP (12.7 ± 1.6 vs. 10.7 ± 0.9 mmHg; p = 0.025) (Table 2). 
However, this effect was accompanied by a significant decrease in mean arterial pressure (−16.7%; p = 0.045) and 
an increase in portosystemic shunting (+68.5%; p = 0.007) (Table 2).
Riociguat reduces serum levels of transaminases and alkaline phosphatase in non-cirrhotic 
patients. Since RIO is available for treatment of pulmonary hypertension, we studied the individual time 
course of transaminase levels in 27 non-cirrhotic patients with pulmonary hypertension and associated heart 
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failure with preserved ejection fraction (PH-HFpEF) before, at baseline, during and after treatment with RIO 
(Supplementary Fig. S3A, Supplementary Table S1). Notably, during RIO treatment a significant decrease of 
AST (−15%), ALT (−10%) and alkaline phosphatase (AP; −7%) was observed, while levels of gamma-glutamyl 
Figure 2. Riociguat exerts antifibrotic activity in cholestatic and toxic models. (A) Hepatic chromotrope-aniline-
blue (CAB) stained area was quantified to assess fibrosis. In early and in advanced BDL rats, RIO significantly 
reduced CAB stained area. (B) In CCl4 cirrhosis RIO reduced CAB area only in early but not in advanced disease. 
(C) The liver fibrosis marker hydroxyproline content was measured photometrically and corrected to liver weight. 
RIO reduced hepatic hydroxyproline in both, early and advanced BDL rats. (D) No differences regarding hepatic 
hydroxyproline content were notable in early or advanced CCl4 animals receiving RIO. (E) Cytokeratin-19 (CK19) 
immunohistochemistry staining of liver slides were quantified to determine bile ducts. In early BDL-RIO rats less 
biliary proliferation was notable. Representative liver slides are shown in panel A, B and E. *p < 0.05, **p < 0.01, 
***p < 0.001 vs. BDL-VEH, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. CCl4-VEH; two-sided unpaired t-test; n = 5–8 
per group in panel A, C and D - according to Table 1; n = 3–7 per group in panel B and D - according to Table 1.
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transferase (GGT) remained unaffected (Supplementary Fig. S3B–E). Of note, in the time period prior to treat-
ment initiation we did not observe any significant changes, and in a subgroup of patients who discontinued RIO 
(n = 13) the respective values returned back to baseline. We further studied the time course of transaminases, AP 
and GGT in age-matched, non-cirrhotic PH-HFpEF patients receiving standard medical treatment (n = 34). This 
control group had similar baseline parameters (Supplementary Table S1) and presented no significant changes of 
AST, ALT, AP or GGT after treatment initiation (Supplementary Fig. S3F–I).
Cirrhotic patients with cholestatic liver disease show more pronounced decreases in portal 
pressure in response to NO donors than patients with non-cholestatic etiologies. In the ani-
mal studies, BDL rats consistently presented superior results with RIO as compared to CCl4 animals. To fur-
ther investigate a potential etiology-dependent impact of the NO pathway on PHT, we retrospectively reviewed 
hemodynamic response rates of 56 cirrhotic patients undergoing repetitive hepatic venous pressure gradient 
(HVPG) measurements prior and under NO-donor (nitrate) therapy. The patients were subdivided in choles-
tatic or non-cholestatic etiologies of liver disease (Supplementary Fig. S4A). The baseline characteristics between 
these two groups were similar, except for sex and bilirubin content (Supplementary Table S2). Indeed, patients 
with cholestatic cirrhosis (n = 7) showed a significantly higher rate of HVPG response to nitrates (86% vs 43%; 
p = 0.034) compared to patients with alcoholic liver disease or viral hepatitis (n = 49). This was also underlined by 
a trend towards a greater mean HVPG decrease in cholestatic liver disease (−22.1% vs. −9.9% in non-cholestatic 
disease; p = 0.092) (Supplementary Fig. S4B–E).
SO-VEH SO-RIO
p BDL-VEH 





n 6 6 7 7
Weight (g) 374 ± 57 387 ± 27 0.733 366 ± 32 383 ± 35 0.311
MAP (mmHg) 95 ± 20 109 ± 32 0.808 93 ± 10 104 ± 12 0.063
Heart rate (bmp) 277 ± 25 304 ± 45 0.869 272 ± 60 321 ± 62 0.149
SMABF (mL/
min/100 g) 10.3 ± 4.0 10.2 ± 3.6 0.162 14.0 ± 4.1 9.8 ± 4.4 0.122
Portal pressure 
(mmHg) 5.5 ± 1.1 6.4 ± 1.4 <0.001 13.3 ± 2.5 10.1 ± 2.4 0.048
Shunting (%) 1.9 ± 1.8 2.1 ± 1.4 0.092 9.2 ± 8.4 9.5 ± 8.7 0.957
BDL advanced
n 5 5 8 8
Weight (g) 425 ± 29 433 ± 31 0.387 406 ± 39 409 ± 31 0.947
MAP (mmHg) 111 ± 6 95 ± 16 0.164 99 ± 24 92 ± 24 0.351
Heart rate (bmp) 363 ± 60 303 ± 61 0.241 319 ± 56 302 ± 46 0.584
SMABF (mL/
min/100 g) 9.3 ± 1.4 10.1 ± 2.1 0.005 14.3 ± 1.35 13.4 ± 2.4 0.498
Portal pressure 
(mmHg) 6.6 ± 1.1 6.2 ± 1.5 <0.001 15.5 ± 1.6 11.8 ± 2.0 0.003
Shunting (%) 1.39 ± 0.33 1.79 ± 1.30 0.066 19.0 ± 16.2 17.2 ± 15.1 0.680





n 7 6 7 6
Weight (g) 452 ± 30 468 ± 27 0.201 417 ± 43 412 ± 32 0.937
MAP (mmHg) 96 ± 19 93 ± 12 0.356 84 ± 11 81 ± 10 0.626
Heart rate (bmp) 307 ± 40 331 ± 29 0.017 264 ± 12 281 ± 34 0.212
SMABF (mL/
min/100 g) 8.3 ± 2.4 7.7 ± 1.3 <0.001 13.2 ± 1.5 10.7 ± 1.6 0.014
Portal pressure 
(mmHg) 5.88 ± 0.89 5.50 ± 1.61 0.001 8.2 ± 0.9 6.9 ± 0.6 0.016
Shunting (%) 1.15 ± 0.49 1.73 ± 1.50 0.001 25.2 ± 13.6 10.8 ± 6.77 0.061
CCl4 advanced
n 7 7 4 3
Weight (g) 449 ± 50 451 ± 38 0.069 364 ± 28 338 ± 31 0.089
MAP (mmHg) 101 ± 26 113 ± 24 0.397 89 ± 22 112 ± 25 0.434
Heart rate (bmp) 297 ± 47 323 ± 61 0.161 265 ± 99 305 ± 7 0.212
SMABF (mL/
min/100 g) 8.8 ± 1.4 9.7 ± 2.1 <0.001 19.3 ± 4.5 13.2 ± 3.0 0.204
Portal pressure 
(mmHg) 5.1 ± 1.8 5.2 ± 0.8 <0.001 11.6 ± 2.5 11.2 ± 2.3 0.852
Shunting (%) 2.1 ± 1.4 2.0 ± 1.9 <0.001 57.3 ± 24.4 39.5 ± 6.7 0.188
Table 1. Hemodynamics of early/advanced BDL and CCl4 rats.
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Discussion
Impairment of the NO/sGC/cGMP pathway represents a major determinant of the increased intrahepatic vascu-
lar resistance in patients with cirrhosis, and thus is a promising target for the treatment of portal hypertension11. 
Here, we show that direct sGC stimulation by RIO does not only decrease portal pressure, but also reduces hepatic 
inflammation and liver fibrosis. The beneficial effects of RIO were most pronounced in rats with cholestatic (BDL) 
cirrhosis and in early toxic (CCl4) cirrhosis.
Most importantly, we observed clinically relevant decreases of portal pressure in early CCl4 cirrhosis (−16%), 
in early cholestatic (−24%) and advanced cholestatic (−24%) cirrhosis without significant effects on mean arte-
rial pressure. Moreover, in cirrhotic animals RIO did not affect splanchnic blood flow or portosystemic shunting, 
suggesting that the vasodilatory effects of sGC stimulation seem to prevail in the damaged hepatic sinusoids. Of 
note, previous studies using NO donors29,30 or PDE5i28,31 (which act up- and downstream of sGC) have led to 
conflicting results regarding amelioration of PHT. Lack of intrahepatic specificity and less antifibrotic activity 
Figure 3. Riociguat improves intrahepatic vasodilation and vascular dysfunction. Western blots were 
performed to determine intrahepatic protein concentrations of markers of vascular contraction (total 
moesin [t-moesin], p-moesin, myosin), vascular dilation (t-eNOS, p-eNOS) and angiogenesis (VEGFR2, 
PDGFβ) in rats with (A,B) early and (C,D) advanced BDL cirrhosis. Values were normalized to expression 
of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as housekeeping protein. (A) BDL significantly 
increased hepatic moesin phosphorylation and myosin content in rats with early BLD cirrhosis, which was 
counter-regulated by RIO treatment. (B) VEGFR2 and PDGFβ expression increased significantly in early 
BDL rats, whereas after RIO treatment expression of both remained low. (C) RIO tended to normalize moesin 
phosphorylation and myosin content in rats with advanced BDL. (D) While eNOS protein content and 
phosphorylation were increased by RIO therapy, VEGFR2 and PDGFβ expression remained unchanged in 
advanced BDL-RIO animals. (E,F) Representative Western blots of early [a-h] and advanced [i-p] BDL animals. 
Full-length blots are presented in Supplementary Figure S5. *p < 0.05, **p < 0.01, ***p < 0.001 vs. BDL-VEH; 
two-sided unpaired t-test; n = 3 per group in panels A, C, E n = 2-3 per group in panels B, D, F.
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might be a reasons for these inconclusive observations. While NO donors are indeed vasodilatory drugs, NO 
itself also leads to detrimental side-effects via other pathways, thus promoting inflammation, HSC apoptosis or 
even liver fibrosis32,33. Furthermore, in cirrhotic HSCs, NO donors failed to increase cGMP production and thus 
vasodilation34, probably because long-term NO exposure decreases sGC mRNA stability35. PDE5i are also potent 
vasodilators, yet the hepatic PDE5 expression is weak as compared to other organs36,37.
In contrast to NO the sGC pathway focuses primarily on vasodilation, and in contrast to PDE5, the sGC 
enzyme is highly expressed in the liver, especially in HSCs and portal venules38. This is supported by our novel 
finding, that after BDL hepatic sGC expression is further upregulated, particularly in HSCs, hepatocytes and 
Figure 4. Riociguat reduces hepatic inflammation. RT-PCR was performed in liver tissue to screen for 
expression changes of inflammatory marker. (A) In the early BDL model expression differences were mostly 
non-significant, when compared to SO-VEH. Yet, in RIO treated animals mean VCAM and TNFα were 
decreased by 48.5% and 46.7%, respectively. (B) In advanced BDL animals, RIO significantly decreased TNFα 
and tended to reduce MCP1 expression. (C) Western Blotting was used to measure hepatic TNFα protein 
content, which significantly decreased in BDL rats receiving RIO. (D) Transaminases AST and ALT were 
measured in serum samples. RIO caused a significant decrease of AST and a trend towards lower ALT levels in 
rats with advanced BDL. (E) Hepatic immunohistochemistry stainings of CD68 positive cells were quantified 
to assess macrophage infiltration. In advanced BDL rats CD68 positive cell content was significantly decreased 
after RIO treatment. Full-length blots of the cropped lines [q, r] are presented in Supplementary Figure S5. 
*p < 0.05, **p < 0.01, ***p < 0.001 vs. BDL-VEH; two-sided unpaired t-test; n = 5–8 per group in panel A, B, D 
and E - according to Table 1; n = 3 per group in panel C.
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Kupffer cells. Of note, we observed in HSCs of cholestatic BDL animals not only an increased expression of the 
more active β1 subunit, but also downregulation of the futile β2 subunit. This expression shift particularly sup-
ports production of the two most active sGC isoforms α2β1 and α1β139. The observed intrahepatic sGC expres-
sion changes might occur due to a lack of NO40 and deteriorated oxygen metabolism41. Additionally this might 
explain, why sGC stimulation exerts its vasodilatory effects mainly in the cirrhotic intrahepatic microcirculation.
In the non-cirrhotic PPVL model RIO also decreased portal pressure, yet this occurred through other mech-
anisms, since in these animals the liver architecture is not altered. In PPVL rats we observed a concomitant 
reduction in systemic arterial pressure and an increase in portosystemic shunting. This suggests that in absence 
of cirrhosis, vasodilatory effects are more apparent on the systemic, splanchnic and collateral vasculature. In 
addition, the high degree of portosystemic shunting (typical for the PPVL model) decreases the hepatic first pass 
effect and leads to increased systemic exposure of RIO. Furthermore, due to the fixed prehepatic surgical portal 
stenosis, intrahepatic vasodilation is ineffective to decompress the portal system. Moreover, in PPVL animals 
sGC stimulation might have a higher impact of on the systemic circulation, because arterial cGMP levels remain 
normal (and thus are more susceptible to sGC stimulation), whereas in cirrhosis arterial cGMP levels are already 
upregulated42. Ultimately the RIO-treatment induced increase in shunting and reduction of mean arterial pres-
sure in PPVL rats are hemodynamic safety signals, which may limit its use in non-cirrhotic portal hypertension.
Figure 5. Hepatic stellate cell activation in vitro and in vivo. (A) Cultured LX-2 HSCs were treated for 48 h with 
10 µM RIO or vehicle, followed by RT-PCR of αSMA mRNA expression. RIO caused a mild but significant 
decrease in αSMA expression compared to controls. (B) Hepatic αSMA protein content was measured by western 
blotting. It tended to be lower in early BDL rats treated with RIO, while no significant changes were seen in rats 
with advanced BDL. (C) The αSMA positive stained area of liver slides from BDL rats was lower in the RIO 
group, attaining statistical significance in the early setting and also showing a decreasing trend in the advanced 
disease model. (D) Yet, hepatic αSMA stainings from CCl4 cirrhotic rats showed no significant changes after RIO 
treatment. Full-length blots of the cropped lines [s, t] are presented in Supplementary Figure S5. Ψp < 0.05 10 µM 
RIO vs. vehicle control; *p < 0.05, **p < 0.01, ***p < 0.001 vs. BDL-VEH, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. 
CCl4-VEH; two-sided unpaired t-test; n = 6 per group in panel A; n = 2-3 per group in panel B; n = 5–8 per group 
in panel C - according to Table 1; n = 3–7 per group in panel D - according to Table 1.
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The key factor contributing to cirrhotic PHT is increased intrahepatic vascular resistance, which is caused 
by both matrix deposition (fibrosis) and sinusoidal vasoconstriction10. Notably, we could demonstrate that RIO 
exerts beneficial effects not only on the sinusoidal vascular tone but also on liver fibrosis. In line with previous 
reports23,24, we observed a significant reduction of liver fibrotic CAB stained area, decreased hydroxyproline con-
tent and less αSMA-positive myofibroblasts in cirrhotic rats treated with RIO. Additionally, we confirmed that 
RIO also reduces hepatic stellate cell derived αSMA expression24. In order to decipher the anti-fibrotic potential 
of RIO, we used two rat models of toxic and cholestatic cirrhosis, and moreover studied them at two disease 
stages, since antifibrotic effects are more difficult to achieve in advanced cirrhosis. While in the toxic CCl4 model 
benefits of RIO treatment were limited to early cirrhosis, in BDL rats we observed significant improvements of 
PHT and liver fibrosis also in the advanced disease model. The particular effects of RIO in the cholestatic BDL 
model were – at least partly – mediated through a reduction of bile duct proliferation as shown by a decreased 
Figure 6. Hepatic sGC expression is upregulated in BDL rats. Subsets of liver cells were extracted from healthy 
and BDL rats. sGC subunit expression was analysed using RT-PCR. (A,B) In hepatocytes and Kupffer cells BDL 
animals presented a trend towards increased β1 subunit expression. (C) No significant changes were notable in 
LSECs. (D,E) Hepatic stellate cells presented a significant increase of sGCβ1 expression, paired with a reduction 
of the less active sGCβ2. *p < 0.05, **p < 0.01, ***p < 0.001 vs. BDL-VEH; two-sided unpaired t-test; n = 5–6 
in all panels.
SO-VEH




n 5 7 7
Weight (g) 351 ± 13 0.305 338 ± 20 335 ± 14 0.714
MAP (mmHg) 92 ± 8.1 0.634 87 ± 6.3 75 ± 9.5 0.045
Heart rate (bpm) 353 ± 23 0.128 327 ± 26 314 ± 37 0.734
SMABF (mL/
min/100 g) 4.1 ± 1.8 <0.001 11.7 ± 2.2 14.0 ± 1.6 0.446
Portal pressure 
(mmHg) 6.5 ± 1.0 0.005 12.7 ± 1.6 10.7 ± 0.9 0.025
Shunting (%) 8.5 ± 3.9 0.011 45.9 ± 20.1 77.5 ± 13.7 0.007
Table 2. Hemodynamics of PPVL rats.
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CK19 expression. The underlying cellular interplay and effects on cytokine expression have been comprehensively 
described by Xie et. al.24, who showed that sGC activation normalizes the LSEC phenotype and thereby promotes 
HSC quiescence. Thus, sGC activation is capable of reversing sinusoidal capillarisation and inhibiting hepatic 
fibrogenesis.
In our study, in cirrhotic rats riociguat opposed the intrahepatic vasoconstriction. One central pathway of 
NO/cGMP mediated vasodilation is via inhibition of RhoA43. RhoA is a small GTPase, which ultimately phos-
phorylates the motorproteins moesin and myosin and thereby causes vasoconstriction44. In BDL rats intrahepatic 
RhoA is highly upregulated, which contributes to the increased hepatic vascular resistance45,46. Here, we noted 
in RIO-treated BDL animals and also in RIO-treated CCl4 rats a very strong decrease of hepatic phosphoryl-
ated moesin and myosin expression, confirming that RIO promotes sinusoidal vasorelaxation, independent of 
etiology.
RIO ameliorated intrahepatic vascular dysfunction also via other pathways. In line with previous work24, 
we observed that sGC agonism normalized pathological VEGFR2 overexpression and increased expression of 
eNOS in BDL rats. Yet effects on VEGFR2 were most pronounced in early cholestasis, while RIO increased eNOS 
expression and activity in advanced BDL. This suggests different effects of sGC agonism during the time course 
of liver disease. Indeed, there exists a complex and reciprocal interplay between VEGF/VEGFR2 and eNOS/NO 
in PHT. These expressional changes might be caused by cGMP-mediated increase of dimethylarginine dimeth-
ylaminohydrolase47, which supports eNOS availability (by clearing asymmetric dimethylarginine (ADMA)) and 
regulates VEGF expression48. Finally both, reduced VEGFR2 activity and increased eNOS activity have been 
shown to decrease PHT and improve liver fibrosis11,49.
Apart from structural and vasoactive effects, we also noted less inflammation in cholestatic livers of BDL rats 
after RIO treatment, as seen by a decrease of hepatic TNFα expression and monocytes/macrophages infiltra-
tion. These observations were more pronounced in rats with advanced BDL cirrhosis, which also presented with 
decreased liver transaminases after RIO treatment. The anti-inflammatory effects of RIO are in line with other 
experimental studies, showing that sGC agonism reduces TNFα levels, chemotaxis and thus, leucocyte recruit-
ment in the intestine50,51.
Likely both, amelioration of sinusoidal perfusion as well as reduction of intrahepatic inflammation, contribute 
to the decrease of liver fibrosis and portal pressure in RIO treated animals. Of note, the correlation between fibro-
genic/angiogenic biomarkers and changes in portal pressure has also been demonstrated clinically52.
While we intended to use various models of PHT in order to overcome model specific limitations, this 
approach rather revealed etiology-dependent differences in the effects of sGC stimulation on fibrosis and portal 
pressure. Throughout all experiments, the beneficial effects of RIO were more pronounced in cholestatic cirrho-
sis than in the CCl4 model. In a small, retrospective clinical investigation, we also noted a higher proportion of 
HVPG responders to NO donors among patients with cholestatic liver disease as compared to alcoholic/viral 
etiology. Clearly our observations are limited by a small sample size. However, these findings are supported by 
data showing that activation of the NO/sGC pathway also stimulates bile secretion53, which might be of additional 
benefit. Moreover, hepatic sGC expression follows a gradient from the portal triad (high expression) towards the 
central vein (low expression)38. While fibrosis in BDL/cholestatic disease mainly originates from the periportal 
area, in CCl4/alcoholic disease primarily the centrilobular area is affected54,55. These distinct pathophysiological 
characteristics may also explain why RIO is more effective in the cholestatic BDL model as compared to the toxic 
CCl4 model.
Since RIO is already approved for the treatment of pulmonary hypertension, we also studied the effects of RIO 
therapy on levels of transaminases in patients. Interestingly, we noted a significant decrease of AST, ALT and alka-
line phosphatase during RIO therapy. The clinical significance of this finding is limited by absence of obvious liver 
disease, yet these effects were only apparent during the RIO treatment period. While pulmonary hypertension 
and thus, hepatic congestions was improved also in a control group receiving standard medical treatment (with-
out RIO), there were no changes in transaminases over the same time period. This small clinical observation may 
suggest, that RIO could have hepatoprotective properties also in humans. Of note, RIO has already been tested 
in patients with liver cirrhosis to assess its safety profile: Besides slower drug excretion and thus increased RIO 
exposure, no safety concerns were raised in Child B patients, thus encouraging its use also in cirrhotic patients if 
doses are adjusted to hepatic function56.
In conclusion, we demonstrate that sGC stimulation by riociguat ameliorates portal hypertension, reduces 
liver fibrosis and inhibits hepatic necroinflammation – especially in cholestatic cirrhosis. Our data would suggest 
that riociguat is most beneficial in patients with compensated (early) biliary cirrhosis, which should be explored 
in prospective clinical trials.
Methods
Ethics. This animal study was approved by the Animal Ethics Committee of the Medical University of Vienna 
and the Federal Ministry of Science, Research and Economy (BMWFW-66.009/0354-WF/V/3b/2014, BMWFW-
66.009/0002-WF/V/3b/2016) and was performed according to the Animal Research: Reporting of In Vivo 
Experiments (ARRIVE) guidelines. Also, the human observations were approved by the Ethics Committee of the 
Medical University of Vienna (EK-Nr. 2010/796, EK-Nr. 2009/497) and conducted according to the Declaration 
of Helsinki. Written informed consent was obtained from each patient included in the study.
Rat models of cirrhosis and portal hypertension. Cholestatic cirrhosis was induced in male Sprague 
Dawley rats (age 6–8 weeks, 280–330 g) by BDL. BDL animals were maintained for 3 weeks to induce early cirrho-
sis and for a 5 week duration to induce advanced cirrhosis Fig. 1. Respective controls underwent sham operation 
(SO).
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To induce toxic cirrhosis, rats received iterative intraperitoneal carbon tetrachloride injections (50%v/v CCl4 
diluted in olive oil, 4 weeks twice weekly, followed by 4 weeks three times weekly) for a total of 8 weeks. Controls 
received olive oil (OO). We used the 50%v/v CCl4 solution at a dose of 1 mL/kg to induce early cirrhosis, and 
2 mL/kg for development of advanced cirrhosis. According to a sample size calculation (based on the hypothesis 
that RIO treatment reduces PP by >20%), these four cirrhotic groups comprised 26 animals each, which were 
randomly assigned.
Non-cirrhotic prehepatic PHT was induced by PPVL using a 20 G blunt-tipped needle as previously 
described8. Healthy controls underwent SO. For this non-cirrhotic group 19 animals were assigned. Hence a 
total of 123 rats were used for these experiments. All animals received standard pellet chow (V1534, sniff GmbH, 
Germany), had access to fresh water, were housed in pairs of three in Makrolon cages (T3) with woody litter and 
followed a 12/12 h light/dark cycle.
Treatment with riociguat and vehicle. All groups received daily gavage of 1 mg/kg RIO (MedChem 
Express, Cat.No.: HY-14779, purity: 99.73%, Sollentuna, Sweden) dissolved in VEH (50% dimethyl sulfoxide) or 
VEH (1 mL/kg) only Fig. 1. The weight-adjusted treatment was administered during the last two weeks in BDL/
SO, during the last three weeks in CCl4/OO, and for one week in PPVL animals, respectively.
Hemodynamic measurements. After completion of treatments, hemodynamic measurements were per-
formed under anaesthesia (ketamine 100 mg/kg; piritramide 2 mg/kg) after a 12 h fasted condition as previously 
described9. Mean arterial pressure (MAP) and heart rate (HR) were recorded after cannulation of the femoral 
artery (catheter PE-50, Smiths Medical, Kent, UK). Similarly, PP was invasively measured by advancing a cathe-
ter through an ileocolic vein. SMABF was measured using a non-constrictive perivascular ultrasonic flowprobe 
(MA1-PRB, Transonic Systems, Ithaca, NY, USA) placed around the superior mesenteric artery and values were 
normalized to 100 g bodyweight. All hemodynamic parameters were continuously recorded (ML870 PowerLab 
8/30, AD Instruments, Colorado, USA) and analysed using the LabChart7 Pro software. Total portosystemic 
shunting was calculated by mean relative organ distribution of coloured 15 μm microspheres (DYE-TRAK, Triton 
Technology, San Diego, USA) after portal venous (red) and splenic (white) injection. After hemodynamic record-
ings, animals were sacrificed and organs were harvested.
Fibrosis quantification and biochemical analysis. Detailed descriptions regarding histochemistry, 
image analysis, Western blotting, PCR, biochemical assays and in vitro cell culture experiments are included as 
Supplementary Methods.
Human studies. To facilitate translation of the experimental data from bench to bedside two small human 
studies were conducted. First data of a prospective study including patients with postcapillary PH-HFpEF receiv-
ing RIO or standard medical treatment was analysed, regarding their effects on transaminases (AST, ALT), GGT 
and AP. In a second, retrospective study we compared the effects of nitrates on HVPG between cirrhotic patients 
with cholestatic versus non-cholestatic liver disease. Detailed descriptions of these two studies are included in the 
Supplementary Methods.
Data availability. All data generated or analysed during this study are included in this published article and 
its Supplementary Information files.
Statistics. Results are presented as mean ± standard deviation. Distribution of collected values was tested 
using the Kolmogorov–Smirnov test. Normally-distributed unpaired values were compared using a two-sided 
student’s t-test. Non-normally-distributed paired values were compared using the Wilcoxon signed-rank test. 
Fisher’s exact test was applied to assess proportions as it is more accurate with small sample sizes. Primary study 
outcome parameters were the changes in portal pressure and liver fibrosis. GraphPad PRISM 7 (GraphPad 
Software Inc, La Jolla, CA, USA) was used for statistical analyses. Two-sided p-values < 0.05 denoted a statistical 
significance.
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